General Medicine, Nephrology
Dr. Roderick Comunale, M.D.
Dr. Rod has been in private medical practice for more than fifteen years. He is
a double board-certified specialist in Internal Medicine and Nephrology, and has
an extensive background in Alternative Medicine, Diabetes, Hypertension,
Nutrition and Research.
Dr. Rod currently holds faculty positions at U.C.S.D. School of Medicine, and
at Western University School of Osteopathic Medicine, in addition to
participating in numerous Research and Investigational Drug Studies. He is
active throughout San Diego County and on staff at several local hospitals,
holding various administrative roles including Chairman of Medicine at
University Community Medical Center in San Diego.
Dr. Rod has received numerous awards, including America's Top Physicians
(2004-2005). He has published his research in the New England Journal of
Medicine, Kidney International, and numerous other peer reviewed Journals.
CURRICULUM VITAE
Roderick A. Comunale II, M.D., F.A.C.P.
P.O. Box 9032
La Jolla, CA 92038-9032
Tel: (858) 551-0276
Updated: 01/24/2007
HIGH SCHOOL: San Pasqual High School, Escondido, California
1976
COLLEGE: University of California, San Diego, California
1976-1978
Tulane University, Louisiana
B.S. 1978-1980
Loma Linda University, Loma Linda, California
Graduate work-Medical physiology 1980-1981
MEDICAL SCHOOL: Autonomous University of Guadalajara, Mexico
M. D. 1981-1985
AMA approved fifth pathway Clinical Clerkship
University of California, Irvine School of Medicine
Irvine, California 1985-1986
INTERNSHIP: University of Southern California - Los Angeles
County Hospital (UCS - LAC)
Internal Medicine 1986-1987
RESIDENCY: USC - LAC
Internal Medicine (Chairman: Dr. Richard Tannen)
1987 - 1989
FELLOWSHIP: USC - LAC
Nephrology (Chairman: Dr. S. G. Massry)
1989 - 1991
BOARD CERTIFICATION: American Board Internal Medicine (Board Certified)
Subspecialty Board - Nephrology (Board Certified)
Elected Fellow: American College of Physicians
April 1st 2005
CLINICAL
APPOINTMENTS: Medi-cal Advisor
1995 - Present
American Board Internal Medicine
Question writer & Reviewer for certification
examination of General Internal Medicine
1996 - Present
Physician Advisor to California Advantage Insurance
1996 - 1998
Clinical Appointment UCSD School of Medicine
Assistant Professor (voluntary)
1997 Present
Mentor UCSD pre-medical students
1998 - Present
Elected to Board of Directors U. C. S. D Healthcare
(Multi-Cultural IPA- currently Synermd)
2000 - Present
Western University School of Osteopathic Medicine,
Pomona California - Clinical Instructor
2000 Present
University Community Medical Center
Member elective medical executive committee
June 11 2003 Present
American Board Internal Medicine
Examiner for re-certification Board ABIM
Sub-specialty Nephrology
Re-certification 2004
CLINICAL
EXPERIENCE: Clinical Instructor USC School of Medicine
1989 - 1991
Volunteer Staff School of Medicine; Acute Hemodialysis; CAVH; CAVHD; Chronic Hemodialysis; CAPD; out-patient Nephrology; out-patient transplant; out-patient Internal Medicine; Transplant (USC - St. Vincents under Dr. Robert Mendez)
CLINICAL
APPOINTMENTS: Mentor UCSD Pre-Medical Division Advisor
1998 Present
Clinical Instructor - Western University School of Osteopathic Medicine, Pomona California
2000 - Present
COMMITEE: Pharmacy & Therapeutics Committee - CHG
1996
Vice - Chairman Medicine Committee - Paradise Valley Hospital
1994 - 1998
Member Medicine / ICU Committee - Paradise Valley Hospital
1994 - 2000
Member Quality Assurance Committee - Paradise Valley Hospital
1994 - 2000
Member Rehabilitation Committee - Paradise Valley Hospital
1997 2000
Member QA/UR UCSD Healthcare
Multicultural IPA
1999 2003
Chairman QA/UR UCSD Healthcare Multicultural IPA
1999 - 2002
Chairman - Pharmacy, Nutrition & Therapeutics Committee -Vencor Hospital
2001 Present
Member Medicine / ICU / Radiology / Pathology Committee Paradise Valley Hospital
2002 Present
Director of Alternative Medicine Villa View Hospital
2002 - Present
Director of Nephrology University Community Medical Center, Quantum healthcare San Diego
March 2002 - Present
Kindred Medical Executive Committee/Governing Board, San Diego
January 2004 Present
Member Quality Council
Kindred Hospital, San Diego
January 2004 Present
Member Dialysis Committee
Alvarado-Tenet Healthcare, San Diego
2004 -
LICENSURE: CALIFORNIA Medical License
Physician Assistant Supervisor License
ORGANIZATIONS: American Medical Association
American College of Physicians
American Institute of Stress 2000 Present
American Society Nephrology 2005 - Present
Alliance Renal Care
Fellow of American Institute of Stress
California Medical Association
San Diego County Medical Association
Nomination April 6 2005 to the National Physician
Ambassadors Program Delegation
RESEARCH
EXPERIENCE: Multi-Center, Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Quetiapine 300mg Tablet (Test) and Seroquel (Reference) Following a 300mg Dose Twice Daily for 5 Consecutive Days in Adult Schizophrenic Patients Under Fasting Conditions.
Protocol number: PLIVA 60683
January 2007
Johnson & Johnson Pharmaceutical Research & Development
January 2007
Johnson & Johnson Pharmaceutical Research & Development
November 2006
Protocol ID A7501021
October 2006
Memory-MEM 1003-101
October 2006
Vanda Pharmaceuticals Inc
A randomized, double-blind, placebo-and ziprasidone-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of a 24mg/day dose iloperidone given b.i.d. for 28 days to schizophrenic patients in acute exacerbation followed by a long-term treatment phase
September 2006
Pfizer
A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluation the Safety and Efficasy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients with an Acute Manic Episode.
Sub-Investigator
June 2006
Pfizer
A Mulitcenter, randomized, double-blind, flexible-dose, 6-week trial of the efficacy and safety of Asenapine compared with placebo using Olanzapine Positive control in subjects with an Acute exacerbation of schizophrenia
Sub-Investigator
June 2006
Rinat Neuroscience Corporation
Protocol # $N624-CL006
Sub-Investigator
April 2006
Solvay Pharmaceuticals
A Randomized, Double-Blind, Placebo-Controlled, Risperidone Referenced Dose Finding Study of DU 127090 in the Treatment of Schizophrenia
GalaxoSmithKline
SB-773812
Sub-Investigator
January 2006
Acadia
Protocol Number ACP-104-002
N-desmethylclozapine
January 2006
Keys Study
Protocol Number: HMR3647A/4019
December 2005
Aventis
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Clinical Health Outcomes of Telithromycin versus Azithromycin in Outpatients with Community-Acquired Lower Respiratory Tract Infections
Sub-Investigator
November 2005
Protocol Number: NAA104606
A Multi Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Adaptive, Dose-Range Study to Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults with Schizophrenia
Sub-Investigator
November 2005
LY170053 1D-US-HGLS Olanzapine Versus Aripiprazole in the Treatment of Acutely III Patients with Schizophrenia
Sub-Investigator
November 2005
Pfizer
A Double-Blind, 40-Week Continuation Study Evaluating the Safety of Asenapine and Olanzapine in the Treatment of Subjects with Acute Mania
Sub-Investigator
October 2005
Solvay Pharmaceuticals
A Randomized, Double-Blind, Placebo-Controlled, Twice Daily Titration Study of the Safety and Tolerability of Bifeprunox in Subjects with Schizophrenia
Sub-Investigator
October 2005
ACADIA Pharmaceuticals
A 140day, steady-state, double-blind, placebo-controlled, multiple escalating dose study of the safety and tolerability of ACP-104 in subjects with chronic schizophrenia, schizoaffective disorder, or chronic psychosis.
October 2005
Aventis
Protocol number Ketek HMR3647A/4019
A Randomized, Double Blind, Parallel-Group, Multicenter Study to compare Clinical Health Outcomes of Telithromycin versus Azithromycin in Outpaients with Community-Acquired Lower Respiratory Tract Infections
Sub-Investigator
October 2005
Sanofi-synthelabo
A Double-Blind, Eight-Week, Placebo and Risperidone controlled, Dose-Finding Study to Evaluate the Efficasy, Safety, and Tolerability of DR142801 in the Treatment of Patients with Schizophrenia or Schizoaffective Disorder.
Sub-Investigator
October 2005
Sanofi-synthelabo
FID-MC-HGJZ: A Double-Blind Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
Sub-Investigator
October 2005
Solvay Pharmaceuticals
Protocol Number S1543001A A randomized, double-blind, placebo-controlled and Risperidone reference, parallel group efficacy & Safety Study of Two fixed doses of Bifeprunox in the Treatment of Schizophrenia
September 2005
Pfizer
A Double-Blind, 9-week Extension Study Evaluating the Safety and Maintenance of Effect of Asenapine vs. Olanzapine in the Treatment of Subjects With Acute Mania.
Protocol number A7501006 / Center No #4041
Pfizer
A Double-Blind, 40 week Continuation Study Evaluating the Safety of Asenapine & Olanzapine in the Treatment of Subjects with Acute Mania
Protocol #: A7501007
Sub-Investigator
July 2005
J & JPRD
Protocol: R076477-SCH-1009
Sub-Investigator
June 2005
Forest Research Institute
Protocol: MEM-MD-27
Sub-Investigator
June 2005
Solvacy Study #51543001 U.C.M.C.
Eli Lilly & Company
Investigator Protocol: F1D-MC-HGJZ(b)
A Double-Blind Randomized Study Comparing Intramuscular Olanzapine Depot with Placebo in the Treatment of Patients with Schizophrenia.
March 2005 - Present
Eli Lilly & Company
Sub-Investigator Protocol: FID-US-HGLS
September 2004- Present
Eli Lilly & Company
Sub-Investigator Protocol: F1D-US-HGLF
July 2004 Present
Johnson & Johnson PRD
Sub-Investigator Protocol: R076477-SCH-102
April 2004 - Present
Bristol-Myers Squibb Protocol: CN 138-131
Sub-Investigator
April 2004 Present
Abbott Protocol: M02-540
Sub-Investigator
March 2004 Present
Choir Study Protocol PR00-06-014
Correction of Hemoglobin and Outcomes in Renal Insufficiency
Sub-Investigator
March 2004 - Present
Johnson & Johnson PRD Protocol: R076477-SCH-301
Sub-Investigator
February 2004 Present
Sanofi-Sythelabo Protocol: DFI5413
Sub-Investigator
February 2004 - Present
Pfizer Protocol: A1281110
Sub-Investigator
February 2004 Present
Solvay Protocol: S1543001 & 3002
Sub-Investigator
February 2004 Present
GlaxoSmithKline
NPP30005
Sub-Investigator
January 2004 Present
Jansen RIS-SCP-402
Sub-Investigator
January 2004 Present
Abbott M02-540
Sub-Investigator
January 2004 Present
AstraZeneca 5077IL/0041
Sub-Investigator
January 2004 Present
Organon
Protocol # 041-006
A double-blind, placebo-controlled, relapse prevention trial with lead-in open-label flexible dose phase with Org 5222 (Asenapine) in the treatment of stable outpatients with schizophrenia
Sub-Investigator
January 2004 Present
Organon
Protocol # 041003
An assessment of two doses of Org 5222 (Asenapine) compared to risperidone on the effects on primary persistent negative symptoms as measured by the Scale for the Assessment of Negative Symptoms in a randomized, double-blind, multicenter, fixed dose, placebo controlled 12 week trial following a 4 week open-label olanzapine lead-in period in patients with schizophrenia or schizoaffective disorder, depressive type
Sub-Investigator
January 2004 - Present
Bristol-Myers Squibb
Protocol: CN138-113
Sub-Investigator Jan 2004 -
AstraZeneca Study Number 50771L/120
Sub-Investigator
Protocol XRP4563-/3501
Sub-Investigator May 2002 -
Mifepristone/Corcept Protocol #C 1073-04
Sub-Investigator Feb 2002 -
Protocol C-1073-02 A Phase III, Randomized, Double-Blind Placebo-Controlled Study of Safety and Efficacy of C-1073 (Mifepristone) in Patients with Major Depressive Disorder with Psychotic Features.
Sub-Investigator October 2001-
Protocol H4Q-MC-ARRI, LY333328 versus Vancomycin in Complicated Skin/Skin-Structure Infections.
Sub-Investigator/Approved by Lilly:March 21 2001
K+ Induced Insulin Secretion in CRF -role of PTH
&n